Cargando…
晚期非小细胞肺癌MET扩增介导获得性耐药的研究进展
Mesenchymal-epithelial transition factor (MET) amplification is an important driver of resistance in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and the combination of MET proto-oncogene (MET) and EGFR-tyrosine kinase inhibitors (TKIs) has shown promise in over...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9411950/ https://www.ncbi.nlm.nih.gov/pubmed/36002199 http://dx.doi.org/10.3779/j.issn.1009-3419.2022.102.23 |